AbCellera

From Wikipedia, the free encyclopedia

AbCellera Biologics Inc.
Type Public
Nasdaq: ABCL
IndustryBiotechnology
Founded2012 Edit this on Wikidata
HeadquartersVancouver, British Columbia
Revenue443.78 million (2020)
Number of employees
360 (2020)
Websitewww.abcellera.com Edit this on Wikidata

AbCellera is a Vancouver, British Columbia-based biotechnology firm that researches and develops human antibodies. The company is best known for its leading role in the , a project of DARPA's Biological Technologies Office.[1] AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days."[2] Its platform for single-cell screening was initially developed at the University of British Columbia.[3]

History[]

AbCellera was founded in 2012 by biomedical researchers Carl Hansen, Véronique Lecault, Kevin Heyries, Daniel Da Costa and Oleh Petriv. In November 2016, the company received a US$645K grant from the Bill & Melinda Gates Foundation to develop a test for tuberculosis.[4] In September 2018, a $10M series A round of funding was closed.[5] In May 2020, a $105M series B round of funding was closed.[6][7]

In June 2020, the company announced it had begun the world's first study of a potential antibody treatment against COVID-19, with a Phase 1 trial of LY-CoV555 (Bamlanivimab), in collaboration with Eli Lilly and Company.[8]

Other partnerships include collaborations with GlaxoSmithKline, Novartis, Pfizer, Sanofi and Teva Pharmaceutical Industries.[9]

References[]

  1. ^ Niiler, Eric (2020-02-14). "Darpa Cranks Up Antibody Research to Stall Coronavirus". Wired. Condé Nast. Retrieved 2020-02-16.
  2. ^ Cumbers, John (2020-02-05). "The Synthetic Biology Companies Racing To Fight Coronavirus". Forbes. Retrieved 2020-02-16.
  3. ^ Shore, Randy (2017-03-03). "B.C.'s biotech leaders are growing up and going global". Vancouver Sun. Postmedia Network. Retrieved 2020-02-16.
  4. ^ "Grant: AbCellera Biologics Inc". Bill & Melinda Gates Foundation. November 2016. Retrieved 2020-02-16.
  5. ^ McGrane, Clare (2018-09-27). "AbCellera raises $10M for machine-learning fueled antibody discovery platform". GeekWire. Retrieved 2020-02-16.
  6. ^ Gormley, Brian (2020-05-27). "AbCellera Banks $105 Million for Antibodies, Including for Covid-19". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-07-21.
  7. ^ Knapp, Alex. "AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases". Forbes. Retrieved 2020-07-21.
  8. ^ "Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans". Lilly. 1 June 2020. Retrieved 4 June 2020.
  9. ^ "AbCellera collaborates with Novartis for antibody discovery". PharmaTimes. 2019-02-14. Retrieved 2020-02-16.
Retrieved from ""